Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1

Jun 1, 2022, 00:00
10.1016/j.jval.2021.10.015
https://www.valueinhealthjournal.com/article/S1098-3015(21)03181-8/fulltext
Title : Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)03181-8&doi=10.1016/j.jval.2021.10.015
First page : 1010
Section Title : METHODOLOGY
Open access? : Yes
Section Order : 1010

Objectives

Survival extrapolation for chimeric antigen receptor T-cell therapies is challenging, owing to their unique mechanistic properties that translate to complex hazard functions. Axicabtagene ciloleucel is indicated for the treatment of relapse or refractory diffuse large B-cell lymphoma after 2 or more lines of therapy based on the ZUMA-1 trial. Four data snapshots are available, with minimum follow-up of 12, 24, 36, and 48 months. This analysis explores how survival extrapolations for axicabtagene ciloleucel using ZUMA-1 data can be validated and compared.

Methods

Three different parametric modeling approaches were applied: standard parametric, spline-based, and cure-based models. Models were compared using a range of metrics, across the 4 data snapshot, including visual fit, plausibility of long-term estimates, statistical goodness of fit, inspection of hazard plots, point-estimate accuracy, and conditional survival estimates.

Results

Standard and spline-based parametric extrapolations were generally incapable of fitting the ZUMA-1 data well. Cure-based models provided the best fit based on the earliest data snapshot, with extrapolations remaining consistent as data matured. At 48 months, the maximum survival overestimate was 8.3% (Gompertz mixture-cure model) versus the maximum underestimate of 33.5% (Weibull standard parametric model).

Conclusions

Where a plateau in the survival curve is clinically plausible, cure-based models may be helpful in making accurate predictions based on immature data. The ability to reliably extrapolate from maturing data may reduce delays in patient access to potentially lifesaving treatments. Additional research is required to understand how models compare in broader contexts, including different treatments and therapeutic areas.

Categories :
  • Cost/Cost of Illness/Resource Use Studies
  • Decision Modeling & Simulation
  • Economic Evaluation
  • Methodological & Statistical Research
  • Oncology
  • Specific Diseases & Conditions
  • Study Approaches
Tags :
  • chimeric antigen receptor t-cell
  • mixture-cure model
  • non-Hodgkin lymphoma
  • survival extrapolation
Regions :
  • Global
ViH Article Tags :